



## Cellular and Metabolic Reprogramming in Cancer

Guest Editors:

**Dr. Evangelos Kolettas**

**Dr. Maria Georgiadou**

**Dr. Eugenia Roupakia**

Deadline for manuscript  
submissions:

**closed (31 December 2023)**

### Message from the Guest Editors

Dear Colleagues,

Cancer is a heterogeneous disease caused by genetic and epigenetic changes conferring characteristic properties to cancer cells. Cancer cells have the capability to modify and reprogram their cellular metabolism in order to support biomass production and proliferation.

Cellular and metabolic reprogramming can occur in response to both intracellular and extracellular signals, including growth factors and cytokines, ECM remodelling and chronic inflammation. Cellular and metabolic reprogramming contributes to acquired drug resistance to anti-cancer agents, significantly limiting patient survival.

The purpose of this Special Issue is to focus on cutting edge research and cover advances on cellular and metabolic reprogramming in malignancies, including cancer stem cells and differentiation, extracellular matrix remodeling, metabolic switches, and anticancer strategies, their therapeutic potential, benefits, possible complications, and pitfalls of such approaches. We invite authors to submit original and novel review articles on basic and translational research.

- cancer
- stem cells
- differentiation
- cellular reprogramming
- metabolic reprogramming/adaptation





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI